943230-33-9

Upstream product

• 14742-32-6 2-amino-5-phenylfuran-3-carbonitrile 
• 70-11-1 α-bromoacetophenone 
• 943230-32-8 6-phenylfuro[2,3-d]pyrimidin-4(3H)-one 

Downstream Products

• 943230-36-2 6-[(6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]hexanoic acid methyl ester 
• 1073135-81-5 5-bromo-4-chloro-6-phenylfuro[2,3-d]pyrimidine 
• 1208346-50-2 2-(6-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethanol 
• 943230-37-3 6-[(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]hexanoic acid methyl ester 
• 1092938-81-2 methyl 6-{[6-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furo[2,3-d]pyrimidin-4-yl]amino}hexanoate 
• 1092938-03-8 Methyl 6-{[5-(5-methylpyridin-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}hexanoate 
• 1092938-06-1 methyl 6-{[5-(5-formylpyridin-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}hexanoate 
• 1092938-08-3 Methyl 6-{[6-phenyl-5-(5-vinylpyridin-2-yl)furo[2,3-d]pyrimidin-4-yl]amino}hexanoate 
• 1092938-10-7 Methyl 6-{[5-(5-ethylpyridin-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}hexanoate 
• 1192753-48-2 1-phenyl-3-(4-{2-[(6-phenylfuro[2,3-d]pyrimidin-4-yl)-amino]ethyl}phenyl)urea 
• 1610549-16-0 1-(3-chlorophenyl)-3-(5-(2-(6-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea 
• 1610549-25-1 C₁₇H₁₅N₅OS 
• 1226548-50-0 (S)-2-phenyl-2-((6-phenylfuro[2,3-d]pyrimidin-4-yl)amino)ethanol 
• 1209001-74-0 N-benzyl-6-phenylfuro[2,3-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors

Epidermal growth factor receptor inhibitors are of importance in cancer therapy and possibly in the management of pain. Herein, we report a structure-activity relationship study with 29 new 6-aryl-furo[2,3-d]pyrimidin-4-amines, involving modification of the 4-amino group and 6-aryl function. The EGFR activity was especially dependent on having a chiral 4-benzylamino group with correct stereochemistry. Molecular dynamics indicate this to be due to favourable cation-π interactions. The most active inhibitor identified, equipotent to Erlotinib, was substituted with (R)-1-phenylethylamine at C-4 and a N1, N1-dimethyl-1,2-diamine group in para position of the 6-aryl moiety. These new furopyrimidines had a different off-target kinase profile when compared to Erlotinib, and also possessed high activity towards Ba/F3 EGFRL858R reporter cells. Further, comparing the EGFR data of the furo[2,3-d]pyrimidin-4-amines with that of the corresponding thieno- and pyrrolopyrimidines concludes the furopyrimidine scaffold to be highly useful for development of new epidermal growth factor receptor antagonists.

SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic

Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof

The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF

The present application relates to novel substituted furopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.

Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors

Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

Identification, SAR studies, and X-ray Co-crystallographic analysis of a novel furanopyrimidine aurora kinase a inhibitor

Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an in-house compound library to select compounds for testing. A hydrazone fragment conferring Aurora kinase activity and heterocy

Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof

The present application relates to novel, acyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.